TAVR and Pacemakers, New Strategies

Courtesy of Dr. Carlos Fava.

TAVR has been shown beneficial and is constantly being advanced onto lower risk populations, but at present, it is limited (perhaps most importantly in aortic tricuspid valves) by the need for permanent pacemaker implantation (PPMI), especially when it comes to self-expandable valves, as the latest study on low risk populations has shown. 

Pacing with a 0.035” GuidewireThe study looked at 248 severe aortic stenosis patients receiving self-expandable valves EVOLUTE, EVOLUTE PRO and EVOLUTE XL 34. They analyzed looked at implant depth at non-coronary cusp level (SNC).

The procedure was done via femoral access with conscious sedation and local anesthesia. 

Mean age was 83, most patients were men, 5.7% had left bundle branch block, 14.9% had right bundle branch block. Mortality STS score was 6%.


Read also: Latin American Session at TCT 2019.


Post procedural stroke was 2.4% and in-hospital death, and at 30 days was 0.4% and 1.2% respectively.

The need for PPMI was 9.7%, mostly within the first 72 hours (22 of 24 patients). There were no clinical differences between patients requiring PPMI and those who did not.

PPMI predictors were: right bundle branch block, large aortic annulus and aortic root, length of septum: when <5 mm, the need for PPMI was 95% (23-24 patients) but when >5 mm, it was 1.4%.

At multivariable analysis, implant depth >membranous septum (odds ratio: 8.04; 95% confidence interval: 2.58 to 25.04; p < 0.001) and the Evolut 34 XL (odds ratio: 4.96; 95% confidence interval: 1.68 to 14.63; p= 0.004) were independent predictors of PPMI.


Read also: Should Interventional Cardiologists Be Involved in Acute Stroke?


The MIDAS approach (minimum depth in reference to septum), was done in 1200 patients aiming at positioning the device at a depth of < MS length whenever possible, reduced the need for PPMI (9% vs. 3% p=0.003) and the rate of new left bundle branch block (25.8% vs. 9% p>0.001).

Conclusion

The use of MIDAS for self-expandable valve implantation achieved a low and predictable rate of need for PPMI that was significantly inferior to the one previously reported. 

Courtesy of Dr. Carlos Fava.

Original Title: Minimizing Permanent Pacemaker Following Repositionable Self-Expanding Transcatheter Aortic Valve Replacement.

Reference: Hasan Jilaihawi, et al. Am Coll Cardiol Intv 2019;12:1796–807.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Previous article
Next article

More articles by this author

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...